Articles Vol. 67 No. CĐ2-NCKH 05/03/2026

DRUG UTILIZATION AND DRUG INTERACTIONS IN PATIENTS WITH CHRONIC HEART FAILURE HOSPITALIZED AT VINH CHAU TOWN MEDICAL CENTER IN 2023

Trang Thi Ngoc Nhien1,2, Le Truong Han1,2, Do Van Mai1,2
1 Faculty of Pharmacy, Nam Can Tho University
2 Khoa Dược, Trường Đại học Nam Cần Thơ
DOI: 10.52163/yhc.v67iCD2.4423
32 Views
29 Downloads
Keywords
Polypharmacy, chronic heart failure, drug interactions.
Abstract

Background:
Chronic heart failure is a common cardiovascular disease that requires long-term treatment with multiple drug combinations. The use of polypharmacy increases the risk of drug–drug interactions, which may affect treatment effectiveness and patient safety. Therefore, assessing patterns of drug use and drug–drug interactions in the management of chronic heart failure is necessary.

Objectives: To investigate drug utilization patterns and analyze drug–drug interactions among hospitalized patients with chronic heart failure at Vinh Chau Town Medical Center, Soc Trang Province, in 2023.

Materials and Methods: A retrospective cross-sectional descriptive study was conducted on 356 medical records of patients diagnosed with chronic heart failure and treated as inpatients from January 1, 2023 to December 31, 2023. Drug–drug interactions were evaluated using Micromedex and Drug Interaction Facts databases.

Results: Angiotensin-converting enzyme inhibitors (ACEIs) were the most frequently used drug group (33.71%). Regimens combining two drug classes accounted for the highest proportion (32.30%). Clinically significant drug–drug interactions accounted for 32.44%, predominantly classified as severe interactions (67.67%) and mainly related to pharmacodynamic mechanisms (64.82%). The most common interacting drug pairs involved spironolactone, digoxin, furosemide, and captopril, with the spironolactone–digoxin combination being the most frequent (4.48%).

Conclusion: ACE inhibitors were commonly prescribed, and two-drug combination regimens predominated in the treatment of chronic heart failure. Drug–drug interactions were mainly pharmacodynamic in nature, with a considerable proportion classified as severe, particularly involving spironolactone, digoxin, furosemide, and captopril.

References
[1]
McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–3726. Google Scholar
[2]
Page RL 2nd, O'Bryant CL, Cheng D, et al. Drugs that may cause or exacerbate heart failure: A scientific statement from the American Heart Association. Circulation. 2016;134(6):e32–e69. Google Scholar
[3]
Guo H, Yang Y, Chen W, et al. Drug interactions in elderly heart failure patients: prevalence, risk factors, and related adverse drug reactions. Front Pharmacol. 2022;13:870259. Google Scholar
[4]
Hồ Công Khương. Khảo sát tình hình sử dụng thuốc trong điều trị nội trú bệnh suy tim tại Bệnh viện Đa khoa khu vực Bồng Sơn, tỉnh Bình Định năm 2018. Luận văn tốt nghiệp Dược sĩ đại học. Trường Đại học Duy Tân; 2019 Google Scholar
[5]
McMurray JJV, Packer M, Desai AS, et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993-1004. Google Scholar
[6]
Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014;13(1):57–65. Google Scholar
[7]
Thomas, Russel W.; Maddox, Ray R. The Interaction of Spironolactone and Digoxin: A Review and Evaluation. Therapeutic Drug Monitoring. Medical University of South Carolina, Charleston, South Carolina. 3(2): p 117-120. Google Scholar
[8]
De Caterina R, Ammentorp B, Darius H, et al. Management of bleeding complications in patients on oral anticoagulants: clinical practice considerations. Am J Med. 2016;129(11):1063–1070. Google Scholar